Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

October 26, 2018

Stereotactic Radiation Shows Ability to Significantly Extend Survival in Cancer Patients with Multiple Metastasis

News

Patients whose cancer returns at multiple sites after treatment — called oligometastatic cancer — are generally thought incurable, but a recent Phase 2 trial found that a highly precise ... Read more

October 24, 2018

Rubraca Shrank Tumors in Nearly Half of Advanced Prostate Cancer Patients with BRCA Mutations

News

Rubraca (rucaparib), Clovis Oncology‘s PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company ... Read more

October 18, 2018October 18, 2018

Prostate and Small Cell Cancers of the Lung Share Genetic Drivers, Study Finds

News

Small cell cancers — cancers with very poor prognosis that often develop from less-aggressive tumors as a means to evade treatment — may be driven by common mechanisms regardless ... Read more

October 15, 2018

Artificial Intelligence Could Identify Prostate Cancer Patients Likely to Relapse After Surgery, Study Reports

News

A pathology test that uses artificial intelligence could be used to examine prostate cancer samples and predict which patients are likely to relapse after surgery, a study shows. The ... Read more

October 4, 2018

Surgery Plus Radiation Therapy Best at Extending Survival in Locally Advanced Prostate Cancer Patients, Study Says

News

A combination of surgery and radiation therapy is better at extending the survival of men with locally advanced prostate cancer than radiation therapy plus hormone therapy, but is associated ... Read more

October 3, 2018

3 in 4 Americans Unaware Early Prostate Cancer Doesn’t Have Noticeable Symptoms, Study Finds

News

There is still a significant lack of understanding about prostate cancer and its symptoms among people in the U.S., even though more than three million American men are diagnosed ... Read more

September 19, 2018

Study Examines Erleada Add-on for Non-metastatic Castration-resistant Prostate Cancer

News

Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, ... Read more

May 19, 2017

Advanced Prostate Cancer Patients Do Not Benefit from Reolysin, Taxotere Combo, Trial Shows

News

Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial. The trial (NCT01619813) failed to ... Read more

May 17, 2017May 17, 2017

Blocking Aggressive Prostate Cancer’s Fat-burning Mechanism Overcomes Disease’s Resistance to Xtandi

News

A major problem treating an aggressive form of prostate cancer is that it develops resistance to the androgen therapies used to combat it. One solution could be targeting the ... Read more

April 21, 2017April 21, 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

News

Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology ... Read more